Reported Earlier, HUTCHMED Wraps Enrollment In Phase II Gastric Cancer Trial For Savolitinib, Targets Late 2025 China Filing
Benzinga Newsdesk 1 year ago
News
The China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or GEJ adenocarcinoma patients
The China's National Medical Products Administration ("NMPA") has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or GEJ adenocarcinoma patients with MET amplification who have failed at least two lines of standard therapies. If positive, HUTCHMED may initiate plans to apply for marketing authorization of savolitinib for gastric cancer in China in late 2025.